Rejoinder to "Statistical inference problems in sequential parallel comparison designs".

J Biopharm Stat

Division of Biometric I, Office of Biostatistics, Office of Translational Sciences, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, USA.

Published: June 2020

In this rejoinder the authors stipulate further for two challenging issues. First, if placebo non-responders are selected simply by their response meeting a threshold, this selection may have misclassification error and consequently the treatment effect estimate may be biased, regardless of whether the estimand at the second stage is the treatment effect in the entire population or placebo non-responders. Secondly, the weak null hypothesis considered in our article is that the expected treatment effects in placebo non-responders and in the entire set of patients entering the trial are both zero, in contrast to the strong null hypothesis that the statistical distribution of the response variable is equal in the compared treatments. The impact of violating the assumption of equal moments other than the mean parameter on statistical operating characteristics in estimation and testing of treatment effect can be substantial. As an example, the ordinary least squares based test detects a treatment difference even if the expected treatment effects in placebo non-responders and the entire population are both zero.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10543406.2019.1609017DOI Listing

Publication Analysis

Top Keywords

placebo non-responders
16
entire population
8
null hypothesis
8
expected treatment
8
treatment effects
8
effects placebo
8
non-responders entire
8
treatment
6
rejoinder "statistical
4
"statistical inference
4

Similar Publications

Background: Previous research has demonstrated that placebo induction manipulations can reduce an individual's pain through non-specific mechanisms, such as expectancy manipulations. However, despite robust research characterizing these effects, individual differences in predicting placebo analgesic responses are not well understood.

Methods: Fifty-four healthy pain-free adults over 18 (M=22.

View Article and Find Full Text PDF

Unlabelled: Intake of New Zealand blackcurrant (NZBC) extract for 7 days has been shown to improve high-intensity intermittent running (HIIR) performance.

Objectives: We examined the repeat response of NZBC extract on HIIR performance.

Methods: Sixteen active males (age: 23 ± 3 yrs, height: 179 ± 5 cm, mass: 79 ± 11 kg, V˙O: 55.

View Article and Find Full Text PDF

Unlabelled: Although evidence-based treatments for Prolonged Grief Disorder (PGD) exist, pretreatment characteristics associated with differential improvement trajectories have not been identified. To identify clinical factors relevant to optimizing PGD treatment outcomes, we used unsupervised and supervised machine learning to study treatment effects from a double-blinded, placebo-controlled, randomized clinical trial. Participants were randomized into four treatment groups for 20 weeks: citalopram with grief-informed clinical management, citalopram with prolonged grief disorder therapy (PGDT), pill placebo with PGDT, or pill placebo with clinical management.

View Article and Find Full Text PDF

Objectives: This study aimed to assess (1) effects of abatacept on salivary gland histology of Sjögren's disease (SjD) patients, (2) the predictive value of salivary gland histopathological characteristics at baseline for clinical response to abatacept treatment.

Methods: Patients (n=41) who participated in the Dutch ASAP-II and ASAP-III trials and international abatacept trial (IM101603) from whom a labial (n=13) or parotid (n=28) salivary gland biopsy was obtained at baseline and after 24 weeks of treatment with abatacept were included. Biopsies were analysed for SjD related histopathological features before and after abatacept (n=25) or placebo (n=16) treatment.

View Article and Find Full Text PDF

Background: Palbociclib plus an aromatase inhibitor is approved for treatment of patients with ER+/HER2- advanced breast cancer (ABC). In the PALOMA-4 trial, adding palbociclib to letrozole prolonged median progression-free survival in Asian women with ER+/HER2- ABC. Here, we report patient-reported outcomes (PROs) from PALOMA-4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!